Literature DB >> 19174176

The immunogenicity of CpG-antigen conjugates.

Hermann Wagner1.   

Abstract

Compared to "live" vaccines the immunogenicity of "split" vaccines is notably poor, because exogeneous antigens (Ag) insufficiently access the MHC class I processing pathway needed for cross-presentation. Here we review our evidence that targeting ligands of endosomally expressed Toll-like Receptors (TLRs), together with exogeneous Ag to endosomes of dendritic cells (DCs) conveys immunogenicity to Ag similar in magnitude as "live" vaccines that produce Ag. We explored the consequences of enforced endocytosis of "Ag plus TLR ligands" either by crosslinking Ag and CpG-Oligonucleotides (CpG-Ag conjugates) or by co-encapsulating Ag plus endosomally expressed TLR ligands in biodegradable microspheres (MP). While both approaches equally well yielded in effective cross-priming of MHC class I restricted CD8 T effector cells, our data recommend MP as a generally applicable endosomal delivery device to vaccinate for protective and therapeutic CD4 and CD8 T cell immunity. Furthermore, our data suggest that functional inactivation of Foxp3(+) regulatory T cells further enhances the immunogenicity of "split vaccines".

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174176     DOI: 10.1016/j.addr.2008.12.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  19 in total

1.  Encapsulating immunostimulatory CpG oligonucleotides in listeriolysin O-liposomes promotes a Th1-type response and CTL activity.

Authors:  Chasity D Andrews; Myung-Sook Huh; Kathryn Patton; Debbie Higgins; Gary Van Nest; Gary Ott; Kyung-Dall Lee
Journal:  Mol Pharm       Date:  2012-04-06       Impact factor: 4.939

2.  Off-the-shelf adenoviral-mediated immunotherapy via bicistronic expression of tumor antigen and iMyD88/CD40 adjuvant.

Authors:  Jan Ole Kemnade; Mamatha Seethammagari; Priya Narayanan; Jonathan M Levitt; Alison A McCormick; David M Spencer
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

Review 3.  Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.

Authors:  Egest J Pone; Hong Zan; Jingsong Zhang; Ahmed Al-Qahtani; Zhenming Xu; Paolo Casali
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

4.  A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.

Authors:  Vishal J Sindhava; Michael A Oropallo; Krishna Moody; Martin Naradikian; Lauren E Higdon; Lin Zhou; Arpita Myles; Nathaniel Green; Kerstin Nündel; William Stohl; Amanda M Schmidt; Wei Cao; Stephanie Dorta-Estremera; Taku Kambayashi; Ann Marshak-Rothstein; Michael P Cancro
Journal:  J Clin Invest       Date:  2017-03-27       Impact factor: 14.808

5.  In vivo NIR-II structured-illumination light-sheet microscopy.

Authors:  Feifei Wang; Zhuoran Ma; Yeteng Zhong; Felix Salazar; Chun Xu; Fuqiang Ren; Liangqiong Qu; Anna M Wu; Hongjie Dai
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

Review 6.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

7.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

Review 8.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

9.  Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates.

Authors:  Haesun Park; Lauren Adamson; Tae Ha; Karl Mullen; Shoko I Hagen; Arys Nogueron; Andrew W Sylwester; Michael K Axthelm; Al Legasse; Michael Piatak; Jeffrey D Lifson; Juliana M McElrath; Louis J Picker; Robert A Seder
Journal:  J Immunol       Date:  2013-03-15       Impact factor: 5.422

10.  Improved protection against Chlamydia muridarum using the native major outer membrane protein trapped in Resiquimod-carrying amphipols and effects in protection with addition of a Th1 (CpG-1826) and a Th2 (Montanide ISA 720) adjuvant.

Authors:  Delia F Tifrea; Sukumar Pal; Christel le Bon; Melanie J Cocco; Manuela Zoonens; Luis M de la Maza
Journal:  Vaccine       Date:  2020-04-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.